TA183: Cervical cancer (recurrent) - topotecan
This is a discussion on TA183: Cervical cancer (recurrent) - topotecan within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Cervical cancer (recurrent) - topotecan . It links to the published guidance and key ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
04-01-2010, 12:51 PM
|
|||
|
|||
TA183: Cervical cancer (recurrent) - topotecan
The summary for the published technology appraisal on Cervical cancer (recurrent) - topotecan . It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA184: Lung cancer (small-cell) - topotecan | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA184: Lung cancer (small-cell) - topotecan | industry_news | Updates from the Technology Assessment Authorities | 0 | 11-25-2009 01:08 AM |
| TA183: Cervical cancer (recurrent) - topotecan | industry_news | Updates from the Technology Assessment Authorities | 0 | 10-22-2009 08:11 AM |
| Topotecan Combination No Extra Help in Ovarian Cancer | industry_news | Other Clinical Pharmacy News | 0 | 07-30-2008 10:37 AM |
© 2008 DrugManagementForum™ powered by |
 |